Johnson & Johnson Ordered to Pay $40M in Talcum Powder Verdict

A Los Angeles jury awarded $40 million Friday to two women who said Johnson & Johnson talcum powders caused their ovarian cancer—$18 million to Monica Kent and $22 million to Deborah Schultz and her husband—adding to a wave of litigation that has included a $966 million mesothelioma verdict and thousands of similar claims. The decision comes after a federal judge rejected J&J’s proposed $9 billion bankruptcy settlement, forcing the company back into individual civil litigation; J&J said it will appeal, notes it has won most prior ovarian-cancer trials, and has ceased selling talc-based baby powder amid mounting liabilities.

Analysis

A Los Angeles jury awarded $40 million to two women Friday—$18 million to Monica Kent and $22 million to Deborah Schultz and her husband—finding Johnson & Johnson’s talc products contributed to their ovarian cancer. The verdict amplifies a wave of talc litigation that includes a separate $966 million mesothelioma award and follows J&J’s global discontinuation of talc-based baby powder in 2023 and its replacement with cornstarch in most of North America in 2020.

This outcome follows a U.S. bankruptcy court judge’s April denial of J&J’s proposed $9 billion settlement after finding a faulty voter solicitation process; J&J chose not to appeal that denial and returned to litigating individual claims. The company reversed roughly $7 billion of a previous reserve, says it has settled 95% of filed mesothelioma suits, and reports it has won 16 of 17 prior ovarian-cancer trials, while announcing plans to appeal the latest verdict.

The case sustains moderately negative market sentiment (sentiment score -0.45) and a nontrivial market impact signal (0.35), indicating continued headline-driven volatility and earnings uncertainty. Investors should expect ongoing individual trials, possible additional large verdicts, reserve volatility and reputational risk that will complicate near-term valuation until a comprehensive legal resolution emerges.

Key Decisions for Investors

• Reassess position size in JNJ and consider reducing exposure or applying option-based hedges given ongoing litigation risk highlighted by the $40 million verdict and prior multimillion-dollar awards
• Monitor appeals, individual trial schedules and upcoming quarterly filings for reserve adjustments—any increase or further reversals to talc liabilities will materially affect cash flow and EPS
• If retaining exposure, favor tactical hedges such as protective puts or collars rather than outright aggression because management has won most prior ovarian trials (16 of 17) and reserve activity could offset or defer losses
• Watch procedural and bankruptcy developments around Red River Talc and any renewed settlement negotiations closely, as a change in the legal-resolution framework would be the principal catalyst to re-rate the stock